It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Rhinoviruses and allergens, such as house dust mite are major agents responsible for asthma exacerbations. The influence of pre-existing airway inflammation on the infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is largely unknown. We analyse mechanisms of response to viral infection in experimental in vivo rhinovirus infection in healthy controls and patients with asthma, and in in vitro experiments with house dust mite, rhinovirus and SARS-CoV-2 in human primary airway epithelium. Here, we show that rhinovirus infection in patients with asthma leads to an excessive RIG-I inflammasome activation, which diminishes its accessibility for type I/III interferon responses, leading to their early functional impairment, delayed resolution, prolonged viral clearance and unresolved inflammation in vitro and in vivo. Pre-exposure to house dust mite augments this phenomenon by inflammasome priming and auxiliary inhibition of early type I/III interferon responses. Prior infection with rhinovirus followed by SARS-CoV-2 infection augments RIG-I inflammasome activation and epithelial inflammation. Timely inhibition of the epithelial RIG-I inflammasome may lead to more efficient viral clearance and lower the burden of rhinovirus and SARS-CoV-2 infections.
Viral infections and exposure to inhaled allergens are linked to asthma onset, exacerbations and progression. Here, the authors used controlled experimental rhinovirus infection in patients with and without asthma, and further assessed in vitro the role of house dust mite allergen combined with rhinovirus and SARS-CoV-2 infection. They discovered that rhinovirus-induced activation of epithelial RIG-I inflammasome supresses antiviral immunity, promotes inflammation during asthma exacerbations and aggravates subsequent infection with SARS-CoV-2, particularly upon house dust mite exposure.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details















1 University of Zurich, Swiss Institute of Allergy and Asthma Research (SIAF), Davos Wolfgang, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650); Christine Kühne – Center for Allergy Research and Education (CK-CARE), Davos Wolfgang, Switzerland (GRID:grid.507894.7) (ISNI:0000 0004 4700 6354); Medical University of Bialystok, Department of Regenerative Medicine and Immune Regulation, Bialystok, Poland (GRID:grid.48324.39) (ISNI:0000000122482838)
2 University of Zurich, Swiss Institute of Allergy and Asthma Research (SIAF), Davos Wolfgang, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650); ETH Zurich/University of Zurich, Functional Genomics Center Zurich, Zurich, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650)
3 University of Zurich, Swiss Institute of Allergy and Asthma Research (SIAF), Davos Wolfgang, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650)
4 Institute of Virology and Immunology (IVI), Bern, Switzerland (GRID:grid.438536.f); University of Bern, Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157); University of Bern, Graduate School for Cellular and Biomedical Sciences, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157)
5 University of Zurich, Swiss Institute of Allergy and Asthma Research (SIAF), Davos Wolfgang, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650); Christine Kühne – Center for Allergy Research and Education (CK-CARE), Davos Wolfgang, Switzerland (GRID:grid.507894.7) (ISNI:0000 0004 4700 6354)
6 University of Zurich, Swiss Institute of Allergy and Asthma Research (SIAF), Davos Wolfgang, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650); Christine Kühne – Center for Allergy Research and Education (CK-CARE), Davos Wolfgang, Switzerland (GRID:grid.507894.7) (ISNI:0000 0004 4700 6354); University Children’s Hospital Zurich, Division of Clinical Chemistry and Biochemistry, Zurich, Switzerland (GRID:grid.412341.1) (ISNI:0000 0001 0726 4330); University Children’s Hospital Zurich, Children’s Research Center, Zurich, Switzerland (GRID:grid.412341.1) (ISNI:0000 0001 0726 4330)
7 University of Zurich, Swiss Institute of Allergy and Asthma Research (SIAF), Davos Wolfgang, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650); Universidad San Pablo-CEU, IMMA, Department of Basic Medical Sciences, Facultad de Medicina, Madrid, Spain (GRID:grid.8461.b) (ISNI:0000 0001 2159 0415); Universidad San Pablo-CEU, Centre for Metabolomics and Bioanalysis (CEMBIO), Department of Chemistry and Biochemistry, Facultad de Farmacia, Alcorcon, Spain (GRID:grid.8461.b) (ISNI:0000 0001 2159 0415)
8 Jagiellonian University Medical College, Department of Internal Medicine, Krakow, Poland (GRID:grid.5522.0) (ISNI:0000 0001 2162 9631)
9 Medical University of Bialystok, Department of Regenerative Medicine and Immune Regulation, Bialystok, Poland (GRID:grid.48324.39) (ISNI:0000000122482838); Medical University of Bialystok, Department of Allergology and Internal Medicine, Bialystok, Poland (GRID:grid.48324.39) (ISNI:0000000122482838)
10 University of Zurich, Swiss Institute of Allergy and Asthma Research (SIAF), Davos Wolfgang, Switzerland (GRID:grid.7400.3) (ISNI:0000 0004 1937 0650); University College Cork, Department of Medicine and School of Microbiology, APC Microbiome Ireland, Cork, Ireland (GRID:grid.7872.a) (ISNI:0000000123318773)
11 Wroclaw Medical University, Department of Clinical Immunology, Wroclaw, Poland (GRID:grid.4495.c) (ISNI:0000 0001 1090 049X); ALL-MED Medical Research Institute, Wroclaw, Poland (GRID:grid.512201.5)
12 Imperial College London, National Heart and Lung Institute, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); School of Medicine, Department of Infectious Diseases, Imperial College London, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764)
13 King’s College London, Guy’s Severe Asthma Centre, School of Immunology & Microbial Sciences, London, UK (GRID:grid.13097.3c) (ISNI:0000 0001 2322 6764); St Thomas‘ Hospital, Guy’s & St Thomas’ NHS Trust, London, UK (GRID:grid.425213.3)
14 Imperial College London, National Heart and Lung Institute, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK (GRID:grid.512915.b) (ISNI:0000 0000 8744 7921)
15 Institute of Virology and Immunology (IVI), Bern, Switzerland (GRID:grid.438536.f); University of Bern, Multidisciplinary Center for Infectious Diseases, Bern, Switzerland (GRID:grid.5734.5) (ISNI:0000 0001 0726 5157)
16 Imperial College London, National Heart and Lung Institute, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111); Asthma UK Centre in Allergic Mechanisms of Asthma, London, UK (GRID:grid.512915.b) (ISNI:0000 0000 8744 7921); Imperial College Healthcare HNS Trust, London, UK (GRID:grid.7445.2) (ISNI:0000 0001 2113 8111)